3D Ultrasound Breast Imaging
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT04692818
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- GE Logiq E10 clinical ultrasound scanner — DIAGNOSTIC_TEST2D B-mode, Doppler, and shear wave elastography images of the lesion
- Verasonics research scanner — DIAGNOSTIC_TEST3D B-mode imaging, microvessel imaging, and shear wave elastography
Study Details
The purpose of this research is to study the efficacy of a new ultrasound imaging method for diagnosis of breast mass.
Key Dates
- Start date
- Nov 10, 2021
- Status verified
- May 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 125 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Clinically indicated breast tumor biopsySubjects with breast lesion and are scheduled for clinically-indicated biopsy will have 3D Multimodal Ultrasound Imaging performed
Primary Outcome Measure
BI-RADS Score [ Time Frame: Baseline ]
Central Contacts
- Bobbie Ott507-293-0922
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Shigao Chen, PhD (PRINCIPAL_INVESTIGATOR) Christine lee, MD, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Rochester, MN
By condition
By specialty
By research site
Related Studies
- Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast CancerPHASE2 · Recruiting · Proton Collaborative Group · Scottsdale, Arizona
- The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac StudyRecruiting · UMC Utrecht · Pittsburgh, Pennsylvania
- TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast CancerPHASE1 · Not Yet Recruiting · Baylor College of Medicine · Houston, Texas
- A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast CancerPHASE1/PHASE2 · Recruiting · BriaCell Therapeutics Corporation · Santa Monica, California